Monk BJ, Herzog TJ, Wang G, et al. - In this phase 3 study, researchers contrasted overall survival (OS) of women with platinum-sensitive, recurrent ovarian cancer (ROC) treated with third-line trabectedin (T) + pegylated liposomal doxorubicin (PLD) vs PLD monotherapy. Five hundred seventy-six patients with advanced-relapsed epithelial ovarian cancer were randomly assigned 1: 1 to intravenous infusions of either T + PLD (trabectedin 1.1 mg/m2 for 3 h; PLD 30 mg/m² for 1.5 h, every 3 weeks) or PLD (50 mg/m² for 1.5 h, every 4 weeks). The combination of T and PLD demonstrated no beneficial OS advantage or safety, however, patients with germline BRCA1/2 mutations and/or a PFI of 6–12 months seem to have clinically relevant survival benefit with T + PLD. No new safety signals have been identified.